Search

Displaying results 4481 - 4490 of 7283 in total
  1. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

  2. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    [L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … risk for poor outcomes and creating a significant clinical challenge [A31818].

    Categories: Complex Mixtures
  3. Drug

    Rimacalib

    go.drugbank.com/drugs/DB12571
    Investigational

    Rimacalib has been used in trials studying the treatment of Rheumatoid Arthritis (RA).

  4. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … plasma-derived FVIII, has been deleted and replaced by a 16 amino acid linker.

  5. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. … In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.

  6. Target

    Cyclin-dependent kinase 7

    go.drugbank.com/bio_entities/BE0001913
    TargetHumans

    Catalytic subunit of the CDK-activating kinase (CAK) complex, a master regulator of CDK activity by catalyzing the activating threonine phosphorylation of CDKs (PubMed:41100585). … Initiates transcription by RNA polymerase II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting dissociation from

    Synonyms: TFIIH basal transcription factor complex kinase subunit
  7. Drug

    Levodropropizine

    go.drugbank.com/drugs/DB12472
    Investigational

    Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of Ambroxol and Levodropropizine).

    Mixtures: SUPRATEX DAC
  8. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking

  9. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.

  10. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]